Article Sidebar

Download
PDF (Bahasa Indonesia)
Statistic
Read Counter : 0 Download : 0

Downloads

Download data is not yet available.

Main Article Content

Abstract

Incomplete treatment in patients with gastric disorders, particularly those with comorbidities, may lead to an increase in the number of prescribed medications and a higher risk of drug interactions. Data from Dr. Stefand Clinic in Bekasi indicate that 15% of patients with gastric disorders and comorbidities returned for follow-up treatment within a short period due to incomplete initial therapy. Additionally, 10% of such patients had previously sought treatment at other healthcare facilities before returning to Dr. Stefand Clinic for the same reason. This situation results in an increased number of prescribed medications, often reaching five or more drugs (polypharmacy), thereby raising the potential for drug–drug interactions. This study aims to analyze the potential for drug interactions among patients with gastric disorders at Dr. Stefand Clinic, Bekasi, as part of an effort to promote rational prescribing practices and prevent adverse outcomes from harmful drug interactions. This research is a non-experimental descriptive research using simple random sampling method with retrospective data collection technique. Data analysis used databases www.drugs.com and go.drugbank.com. Data collection was carried out by tracing 366 medical records of patients with gastric disorders and their comorbidities for the period January-December 2021. The results of the study found that there were 361 drug interactions from 366 samples. The most widely used gastric disorders drugs were the proton pump inhibitors class (74,46%), namely Omeprazole (44,72%) and Lansoprazole (29,74%). Single-drug gastric disorders (77,05%) are more prescribed than combination drugs (22,95%) for gastric disorders. The drug interactions between Omeprazole and Cyanocobalamin are 9,57%, with minor severity and pharmacokinetic mechanisms in the absorption phase. In terms of severity, it was found to be ringan, 54,15%, sedang, 42,66%, and berat, 3,19%. The most common drug interaction mechanism is pharmacokinetics, which is 92,72%, with an absorption phase of 27,96%, a metabolism phase of 66,25%, and an excretion phase of 5,79%. There is a significant relationship between the number of drugs prescribed and the number of potential drug interactions (r : 0,571; nilai p 0,000). There is a significant relationship between the number of comorbidities and the number of potential drug interactions (r : 0,767; Nilai p 0,000).

Keywords

Gastric disorders Drug interaction Comorbid Polypharmacy Medical record

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Author Biographies

Sahat Saragi, Program Studi Farmasi, Universitas Pancasila, Jakarta, Indonesia

Program Studi Farmasi, Universitas Pancasila, Jakarta, Indonesia

Steve Albert Napitupulu, Program Studi Farmasi, Universitas Pancasila, Jakarta, Indonesia

Program Studi Farmasi, Universitas Pancasila, Jakarta, Indonesia
How to Cite
Saragi, S., & Napitupulu, S. A. (2026). Analisis Potensi Interaksi Obat Gangguan Lambung Yang Diresepkan Pada Pasien Klinik Dr. Stefand Bekasi. Borneo Journal of Pharmascientech, 10(2), 260-278. https://doi.org/10.59053/bjp.v10i2.797
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Adam, D., Hostalek, U., & Tröster, K. (1995). 5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: Comparison with 10-day penicillin V therapy. Infection, 23(S2), S83–S86. https://doi.org/10.1007/BF01742990
  2. Annisa, N., & Abdulah, R. (2012). Potensi Interaksi Obat Resep Pasien Geriatri: Studi Retrospektif pada Apotek di Bandung. Jurnal Farmasi Klinik Indonesia, 1(3), 96–101. https://jurnal.unpad.ac.id/ijcp/article/view/12672
  3. Bae, Y.-S., Shin, E.-C., Bae, Y.-S., & Van Eden, W. (2019). Editorial: Stress and Immunity. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.00245
  4. Drugs.com. (2025). Drug Interaction Checker. Drugs.Com. https://www.drugs.com/drug_interactions.html
  5. Farikhah, H. N. (2018). Evaluasi Interaksi Obat Potensial pada Pasien Gastritis dan Dispepsia di Rawat Inap RSUD Dr. Moewardi Tahun 2016 [Skripsi, Universitas Muhammadiyah Surakarta]. https://eprints.ums.ac.id/59203/
  6. Finnan, J. L., Rudolph, E. L., & Schmidt, D. N. (1975). Process for preparing spray dried acetaminophen powder and the powder prepared thereby." (Patent US4710519). issued October, 1975. https://www.t3db.ca/toxins/t3d2571
  7. Gobezie, M. Y., Bitew, H. B., Tuha, A., & Hailu, H. G. (2021). Assessment of Potential Drug-Drug Interactions and Their Predictors in Chronic Outpatient Department of Dessie Referral Hospital, Dessie, Northeast Ethiopia. Drug, Healthcare and Patient Safety, 13, 29–35. https://doi.org/10.2147/DHPS.S279371
  8. Handayani, K. (2015). Analisis Potensi Interaksi Obat Diabetes Melitus Pada Resep Obat Pasien Rawat Jalan Di RSAL Dr. Mintohardjo [Skripsi, UIN Syarif Hidayatullah]. http://repository.uinjkt.ac.id/dspace/handle/123456789/29195
  9. Hendera, & Rahayu, S. (2019). Analisis Risiko Interaksi Obat terhadap Resep Pasien Klinik Anak di Rumah Sakit di Banjarmasin (Risk Analysis Of Drug Interactions On Children Recipes Clinic Patients At Hospitals In Banjarmasin). 2(2), 148–153. journal.umbjm.ac.id/index.php/jcps
  10. Kot, M., & Daniel, W. A. (2008). Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacological Reports : PR, 60(6), 789–797. https://pubmed.ncbi.nlm.nih.gov/19211970/
  11. Lamtiar, P., Listyanti, E., Hati, A. K., & Sunnah, I. (2019). Analisis Hubungan Polifarmasi Dan Interaksi Obat Pada Pasien Rawat Jalan Yang Mendapat Obat Hipertensi Di Rsp. Dr. Ario Wirawan Periode Januari-Maret 2019. Indonesian Journal of Pharmacy and Natural Product, 2(2). https://doi.org/10.35473/ijpnp.v2i2.280
  12. Lestari, P., & Wahyuningsih-Politeknik Kesehatan Bhakti Mulia, S. S. (2021). Hubungan Polifarmasi dan Potensi Interaksi Obat Ranitidin Pasen Rawat Inap di RSUD Ir. Soekarno Sukoharjo. Indonesian Journal on Medical Science, 8(1). https://doi.org/10.55181/ijms.v8i1.254
  13. Malik, T. F., Gnanapandithan, K., & Singh, K. (2025). Peptic Ulcer Disease. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK534792/
  14. Marengoni, A., & Onder, G. (2015). Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ (Clinical Research Ed.), 350, h1059. https://doi.org/10.1136/bmj.h1059
  15. Prakoso, R. B. (2016). Potensi Interaksi Obat Pada Pasien Gangguan Lambung (Dispepsia, Gastritis, Tukak Peptik) Rawat Inap di Rumah Sakit “X" Tahun 2015 [Skripsi, Universitas Muhammadiyah]. https://eprints.ums.ac.id/46251/
  16. Rasool, M. F., Rehman, A. ur, Khan, I., Latif, M., Ahmad, I., Shakeel, S., Sadiq, M., Hayat, K., Shah, S., Ashraf, W., Majeed, A., Hussain, I., & Hussain, R. (2023). Assessment of risk factors associated with potential drug-drug interactions among patients suffering from chronic disorders. PLOS ONE, 18(1), e0276277. https://doi.org/10.1371/journal.pone.0276277
  17. Rosenstock, S., Jørgensen, T., Bonnevie, O., & Andersen, L. (2003). Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut, 52(2), 186–193. https://doi.org/10.1136/gut.52.2.186
  18. Sánchez-Valle, J., Correia, R. B., Camacho-Artacho, M., Lepore, R., Mattos, M. M., Rocha, L. M., & Valencia, A. (2024). Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations. BMC Medicine, 22(1), 166. https://doi.org/10.1186/s12916-024-03384-1
  19. Sarri, M. R. (2021). Analisis Hubungan Polifarmasi dan Potensi Interaksi Obat pada Pasien yang Mendapatkan Resep Anti Hipertensi di RSI Siti Khadijah Palembang Tahun 2020. [Tesis, Universitas Sriwijaya]. https://repository.unsri.ac.id/58048/
  20. Setiawan, A. A., Aini, N., & Noviyanto, F. (2016). Evaluasi Penggunaan Obat Tukak Peptik pada Pasien Tukak Peptik (Peptic Ulcer Disease) di Rumah Sakit Bhayangkara Brimob Tahun 2015. Jurnal Farmagazine (Jurnal Ilmiah Kefarmasian), 3(2), 33–38. https://doi.org/http://dx.doi.org/10.47653/farm.v3i2.31
  21. Tajudin, T., Nugroho, I. D. W., & Faradiba, V. (2020). Analisis Kombinasi Penggunaan Obat pada Pasien Jantung Koroner (Coronary Heart Disease) dengan Penyakit Penyerta di Rumah Sakit X Cilacap Tahun 2019. Pharmaqueous : Jurnal Ilmiah Kefarmasian, 1(2), 6–13. https://doi.org/10.36760/jp.v1i2.111
  22. Tiong, H. Y., Huang, P., Xiong, S., Li, Y., Vathsala, A., & Zink, D. (2014). Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models. Molecular Pharmaceutics, 11(7), 1933–1948. https://doi.org/10.1021/mp400720w
  23. Tonini, M., Candura, S. M., Messori, E., & Rizzi, C. A. (1995). Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Pharmacological Research, 31(5), 257–260. https://doi.org/10.1016/1043-6618(95)80029-8
  24. Turner, R. M., de Koning, E. M., Fontana, V., Thompson, A., & Pirmohamed, M. (2020). Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study. BMC Medicine, 18(1), 367. https://doi.org/10.1186/s12916-020-01827-z
  25. Wolff, J., Reißner, P., Hefner, G., Normann, C., Kaier, K., Binder, H., Hiemke, C., Toto, S., Domschke, K., Marschollek, M., & Klimke, A. (2021). Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders. PloS One, 16(7), e0255192. https://doi.org/10.1371/journal.pone.0255192
  26. World Life Expectancy. (2020). World Health Rankings, Indonesia : Peptic Ulcer Disease. https://www.worldlifeexpectancy.com/indonesia-peptic-ulcer-disease
  27. Xu, S., Song, Z., Bai, J., & Wang, J. (2025). Prevalence and clinical significance of potential drug-drug interactions of antimicrobials in Intensive Care Unit patients: a retrospective study. BMC Pharmacology & Toxicology, 26(1), 104. https://doi.org/10.1186/s40360-025-00925-z
  28. Zeind, C. S., & Carvalho, M. G. (2017). Applied Therapeutics: The Clinical Use of Drugs (11th ed.). Wolters Kluwer.
  29. Zhang, J., Ma, D., Chen, M., Hu, Y., Chen, X., Chen, J., Huang, M., & Dai, H. (2024). Prevalence and clinical significance of potential drug-drug interactions among lung transplant patients. Frontiers in Pharmacology, 15, 1308260. https://doi.org/10.3389/fphar.2024.1308260